Sichuan Hebang Biotechnology (603077.SH) issued a profit warning, expecting a 96.88% to 97.66% year-on-year decline in net profit for the fiscal year 2024.
Habio (603077.SH) announces a decrease in performance forecast for the year 2024, expecting a decrease in net profit...
Sichuan Hebang Biotechnology (603077.SH) announced a forecasted decrease in performance for the year 2024, estimating a net profit attributable to shareholders of the listed company of 30 to 40 million yuan, a year-on-year decrease of 96.88% to 97.66%.
Related Articles
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.
A-share hot topics in the evening | NVIDIA invests $5 billion in Intel
Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.
A-share hot topics in the evening | NVIDIA invests $5 billion in Intel
Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
RECOMMEND
Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025
Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025
SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025
